Genmab AS 2023 SR
The report highlights Genmab's 25th anniversary and its progress in developing antibody therapeutics, including the launch of epcoritamab in the U.S., EU, and Japan. The company expanded its workforce to 2,204 members and achieved an 83% employee engagement score. Environmentally, Genmab completed its first full carbon footprint assessment for Scopes 1, 2, and 3 and set a target to reduce Scope 1 and 2 emissions by 42% by 2030. The report also details alignment with UN SDGs 3, 5, 8, and 13 and adherence to TCFD recommendations.
Company: Genmab AS
Sector: Health Care
Country: Denmark
Year: 2023
Type: SR
Pages: 45
Genmab AS
Corporate Responsibility Report
The report highlights Genmab's 25th anniversary and its progress in developing antibody therapeutics, including the launch of epcoritamab in the U.S., EU, and Japan. The company expanded its workforce to 2,204 members and achieved an 83% employee engagement score. Environmentally, Genmab completed its first full carbon footprint assessment for Scopes 1, 2, and 3 and set a target to reduce Scope 1 and 2 emissions by 42% by 2030. The report also details alignment with UN SDGs 3, 5, 8, and 13 and adherence to TCFD recommendations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Renewable Energy
Women on Board
Women in Management
Employees